Navigation Links
Selexys Pharmaceuticals Initiates Enrollment in Phase I Clinical Study of SelG1
Date:5/4/2011

OKLAHOMA CITY, May 4, 2011 /PRNewswire/ -- Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.  

The placebo-controlled, double-blind, first-in-human, ascending single dose and multiple dose study of SelG1 will enroll approximately 30 healthy subjects. This study will evaluate the safety and pharmacology of SelG1 prior to advancement into a Phase II trial in patients with sickle cell disease.

"This Phase I study represents the first step in understanding the potential of SelG1 to address the unmet medical need in sickle cell disease and we are excited to initiate the clinical development of this novel compound," said Dr. Scott Rollins, Selexys President and CEO. "This Phase I trial represents a key milestone for Selexys as we transition from a preclinical to a clinical development stage biopharmaceutical company."

In 2008, Selexys received orphan-drug designation for SelG1 from the Food and Drug Administration Office of Orphan Products Development for the treatment of vasoocclusive crisis, a severe and painful complication of sickle cell disease. Orphan drug designation is awarded to therapeutics with the potential for safe and effective treatment diagnosis or prevention of rare diseases and disorders that affect fewer than 200,000 people.

About SelG1

SelG1 is an investigational humanized monoclonal antibody directed against P-selectin, a key member of the adhesion molecule family known as the selectins. In preclinical studies, inhibition of P-selectin has been shown to effectively prevent vasoocclusion by blocking critical cell-cell interactions that drive this process. Therapeutic blockade of P-selectin may therefore reduce vasoocclusion and subsequent crises in patients with sickle cell disease.

"SelG1 represents a first-in-class therapeutic approach for the treatment of sickle cell disease and potentially other proinflammatory and prothrombotic conditions," stated Dr. Russell Rother, who heads the clinical development program for Selexys. "Effective therapies that target vasoocclusion are needed to address the serious complications in patients with this life-threatening disease."

The SelG1 program for sickle cell disease is supported by a Small Business Innovation Research (SBIR) fast-track award #5R44HL093893-02 through the National Heart, Lung and Blood Institute.

About Selexys Pharmaceuticals

Selexys is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of inflammation and thrombosis across a broad range of severe diseases. Selexys is also developing SelK1, a fully human monoclonal antibody directed against PSGL-1 for the treatment of Crohn's Disease and other inflammatory disorders. Selexys is headquartered in Oklahoma City, OK.  For additional information please visit our website at www.selexys.com.  


'/>"/>
SOURCE Selexys Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aires Pharmaceuticals Appoints Edwin L. Parsley as Chief Medical Officer
2. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
3. MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
6. Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
7. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
8. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
9. Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Isis Pharmaceuticals to Present at the 14th Annual Bank of America Merrill Lynch Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 ... instances of hypertension is driving ambulatory blood pressure monitoring ... their elasticity and their ability to respond to different ... This condition can lead to various cardiovascular disorders such ... vascular disease. These diseases are growing in prevalence each ...
(Date:5/27/2016)... 27, 2016 The healthcare sector ... insurance companies all falling under its umbrella.  A rather ... not often talked about, these healthcare companies are still ... is by far the largest consumer of ... Corp. (OTC: ADMD), Nutranomics Inc. (OTC: NNRX), KollagenX Corp. ...
(Date:5/26/2016)... Tenn. , May 26, 2016 /PRNewswire/ ... of software and analytics, network solutions and ... today announced it entered into a strategic ... provider of outpatient software solutions and revenue ... centers, specialty hospitals and rehabilitation clinics to ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the multiple ... London is home to Ontario’s leading day spa and one of Canada’s few accredited ... with a unique concept to combine spa services with hair and beauty services ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and Education Foundation (OREF) is ... G. Lewallen, MD, began his term as president in March, succeeding John J. Callaghan, ... OREF’s new president-elect. Richard F. Kyle, MD, will serve as chair, corporate development, succeeding ...
(Date:5/31/2016)... , ... May 31, 2016 , ... ... 4, 2016 Cool Vendors in Security Infrastructure Protection report by Gartner1 Inc. , ... a series of research reports evaluating these innovative vendors and their products and ...
(Date:5/31/2016)... ... May 31, 2016 , ... Super Powder, a supplement produced by Prox Formulas ... and dedicated athletes, continues to transform the nutritional supplement industry by providing a safe, ... protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, Omega 3’s, Vit ...
(Date:5/30/2016)... , ... May 30, 2016 , ... Another ER facility ... in Plano, located at 3960 Legacy Drive, Plano, TX and is open 24 hours ... of Commerce followed by a medical open house. The Jasper High School band entertained ...
Breaking Medicine News(10 mins):